MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • Retinal Degeneration
    • Publications
  • News & Media
  • Contact Us
MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • Retinal Degeneration
    • Publications
  • News & Media
  • Contact Us
  •  
  • June 2017

AIVITA Comments on Positive Findings from Asterias’ SCiStar Trial for Spinal Cord Injury

AIVITA Biomedical CEO Hans Keirstead, Ph.D. to Speak at Stem Cell Cures Consortium Conference

AIVITA Biomedical is an immuno-oncology company designing personalized vaccines that target the seed of all cancers: tumor-initiating cells. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development in cancer and other fields.

Recent News

  • AIVITA Biomedical CEO Hans Keirstead Named to “20 in 2020” by Consulate General of Canada for Contributions to COVID-19 Research
  • AIVITA Biomedical Publishes Study Comparing Immune Responses and Associated Survivals Induced by Dendritic and Tumor Cell Vaccines
  • AIVITA Biomedical Provides Update of Ongoing Phase 2 Glioblastoma Trial from Year-End Survival Analysis
  • AIVITA Biomedical Raises $12.5 Million in Series B-2 Financing Round and Announces New Board of Directors Appointee
  • AIVITA Biomedical to Present at 2020 BIO CEO & Investor Conference

Site Navigation

  • About Us
  • Programs
  • News & Media
  • Contact Us
Copyright © 2020 | AIVITA Biomedical, Inc.